.svg)
South Asia’s genetic diversity could hold clues that global studies may have overlooked. Large-scale Indian genome sequencing initiatives like GenomeIndia have uncovered 130 million genetic variants, including 44 million never reported before. These variants could reshape our understanding of inherited disease risk, drug response, and therapeutic targets. Explore how GWAS and secure genomic analysis can turn this untapped evidence into new insights for disease research and target discovery.
.svg)
.png)
.png)
.png)
.png)
Large-scale initiatives such as UK Biobank and FinnGen have demonstrated how to combine genomic and clinical data through GWAS can identify disease-associated variants and inform therapeutic target discovery. Their research models also show how institutions and industry can collaborate through governed access to sensitive genomic data.
South Asian populations remain significantly underrepresented in global genetic studies. India's growing genomic resources present an opportunity to investigate population-specific disease associations and expand the genetic evidence available for drug discovery.
Join Prof. Jitendra Kumar and Dr. Arushi Batra for a panel discussion to explore how data harmonization and federated research environments can make these resources accessible for large-scale analysis. The session will examine how researchers can query genomic datasets, generate approved research outputs, and derive insights while sensitive raw data remains under custodial control.
.svg)
.svg)
%201%20(1).svg)
.svg)
%201.svg){kind=icon}
%201.svg){kind=icon}
.svg)
%20(1).svg)
